

Characteristics and outcomes of patients with pulmonary arterial hypertension transitioning to selexipag from another prostacyclin pathway agent in the SPHERE registry

Murali M. Chakinala, MD,^a Vallerie McLaughlin, MD,^b <u>Harrison W. Farber, MD,^c</u> Kristin B. Highland, MD, MSCR,^d Anna R. Hemnes, MD,^e Kelly M. Chin, MD,^f Michelle Han, PharmD,^g Gurinderpal Doad, PharmD,^g Paul Strachan, MD,^g Michelle Cho, PharmD^g Tobore Tobore, MD, MPH,^g Mohammad Rahman, PhD,^g Nick H. Kim, MD^h

 ^aWashington University School of Medicine, St. Louis, Missouri; ^bUniversity of Michigan Medical Center, Ann Arbor, Michigan; ^cTufts Medical Center, Boston, Massachusetts; ^dCleveland Clinic, Cleveland, Ohio; ^eVanderbilt University Medical Center, Nashville, Tennessee; ^fUniversity of Texas, Southwestern Medical Center, Dallas, Texas; ^gActelion Pharmaceuticals US, Inc, a Johnson & Johnson Company, Titusville, New Jersey; the ^hUniversity of California San Diego, La Jolla, California.



SCHEST[°]



Harrison W Farber, MD

Professor of Medicine and Physiology Director, Pulmonary Embolism Response Team Tufts Medicine Boston, MA, USA

Disclosures: I am a speaker for Bayer (non-branded) and a scientific advisory board member for Actelion, a Johnson & Johnson Company, Acceleron (Merck), Aerovate, Aerami, Roivant, and United Therapeutics

Objective

nce and is not for To describe the characteristics and outcomes of patients with pulmonary arterial hypertension who transitioned to selexipag from another prostacyclin pathway agent, using data from the real-world US SelexiPag: tHe usErs dRug rEgistry (SPHERE)

SelexiPag: tHe usErs dRug rEgistry (SPHERE)



N=759

Adults with PAH

- US, multicenter, prospective, real-world, observational selexipag drug registry
- Followed for up to 18 months
- NCT03278002


Data collected at routine clinical visits and analysis:

- Patient demographics
- Medical history
- Disease characteristics
- WHO functional class
- REVEAL 2.0
- Prior PAH therapy (past 12 months)

- Selexipag dose regimens and titration
- Selexipag discontinuation and reason
- Time to first hospitalization
- Overall survival
- Safety

WHO, world health organization; PAH, pulmonary arterial hypertension

SPHERE registry: Patients with PAH transitioning from a different PPA to selexipag




124 (16%) patients in the SPHERE registry were treated

FC, functional class; PAH, pulmonary arterial hypertension; PPA, prostacyclin pathway agent;


PPA

REVEAL, Registry to Evaluate Early and Long-Term PAH Disease Management; SPHERE, SelexiPag: tHe usErs dRug rEgistry; WHO, World Health Organization.

124 patients with PAH in the SPHERE registry transitioned from another PPA to selexipag



CHD, congenital heart disease; CTD, connective tissue disease; DTI, drug and toxin induced; IPAH, idiopathic pulmonary arterial hypertension; IQR, interquartile range; IV, intravenous; PAH, pulmonary arterial hypertension; PPA, prostacyclin pathway agent; SC, subcutaneous; SPHERE, SelexiPag: tHe usErs dRug rEgistry.



6MWD, 6-minute walk distance; BNP, brain natriuretic peptide; IQR, interquartile range; mPAP, mean pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptidePVR, pulmonary vascular resistance; REVEAL, Registry to Evaluate Early and Long-Term PAH Disease Management; RHC, right heart catheterization; WHO, World Health Organization.


Patient outcomes after transitioning to selexipag

Parameter ^a	All transitioned patients (n=124)	From inhaled (n=58)	From oral (n=14)	From IV/SC (n=52)
Overall survival at 18 months, % of patients (95% CI)	89 (82-94)	90 (78-95)	93 (59-99)	SC: 100 (100-100) IV: 86 (72-94)
WHO functional class change at 18 months, n/N ^b (%)				
Improved	12/58 (21)	7/28 (25)	1/7 (14)	4/23 (17)
Stable	37/58 (64)	17/28 (61)	5/7 (71)	15/23 (65)
Worsened	9/58 (16) ్లర	4/28 (14)	1/7 (14)	4/23 (17)
Reason for permanent selexipag discontinuation, n (%)				
Death	8 (6)	3 (5)	0	2 (4)
AE	24 (19)	11 (19)	0	10 (19)
AE related to PAH progression	⁵⁶¹ 11 (9)	5 (9)	0	4 (8)
Selexipag-related AE	12 (10)	5 (9)	0	5 (10)
Any other reason	11 (9)	5 (9)	1 (7)	5 (10)

Median selexipag maintenance dose among all transitioned patients was 1400 µg twice daily

^aNumbers may not add to 100% due to rounding; ^bPatients with evaluable data at 18 months. AE, adverse event; CI, confidence interval; IV, intravenous; PAH, pulmonary arterial hypertension; SC, subcutaneous; WHO, World Health Organization.

SPHERE registry: Patients with PAH transitioning from a different PPA to selexipag



124 (16%) patients in the SPHERE registry were treated

FC, functional class; PAH, pulmonary arterial hypertension; PPA, prostacyclin pathway agent;

PPA

REVEAL, Registry to Evaluate Early and Long-Term PAH Disease Management; SPHERE, SelexiPag: tHe usErs dRug rEgistry; WHO, World Health Organization.



Thank you!

Don't forget to evaluate this session in the app

Scan the QR code:

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.



URL Link:

https://www.janssenscience.co m/media/attestation/congresse s/pulmonaryhypertension/2024/chest/chara cteristics-and-outcomes-ofpatients-with-pulmonaryarterial-hypertensiontransitioning-to-selex.pdf